Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    ganirelix | Endometriosis
Previous Study | Return to List | Next Study

Cardiovascular Disease Risk in Women With Endometriosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03746535
Recruitment Status : Not yet recruiting
First Posted : November 19, 2018
Last Update Posted : March 23, 2020
Sponsor:
Information provided by (Responsible Party):
Yale University

Brief Summary:
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.

Condition or disease Intervention/treatment Phase
Endometriosis Drug: Ganirelix Acetate Not Applicable

Detailed Description:
Our scientific premise is that in women with endometriosis, elevated cardiovascular disease risk is the result of endothelial dysfunction and chronic systemic inflammation through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 2 cohort clinical trial
Masking: None (Open Label)
Masking Description: no masking, all subjects have endometriosis
Primary Purpose: Treatment
Official Title: Cardiovascular Disease Risk in Women With Endometriosis
Estimated Study Start Date : September 30, 2020
Estimated Primary Completion Date : August 30, 2022
Estimated Study Completion Date : August 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis

Arm Intervention/treatment
Active Comparator: patients without endometriosis
Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
Drug: Ganirelix Acetate
Ganirelix acetate alone, 250 μg/day in 0.5 ml normal saline,

Experimental: patients with endometriosis
Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
Drug: Ganirelix Acetate
Ganirelix acetate alone, 250 μg/day in 0.5 ml normal saline,




Primary Outcome Measures :
  1. Flow Mediated Vasodilation Microvascular skin blood flow analysis [ Time Frame: 2 minutes ]
    Blood flow velocity will be measured using the Sonoscope S2 ultrasound imaging system.

  2. Flow Mediated Vasodilation Microvascular skin blood flow analysis [ Time Frame: 2 minutes ]
    Brachial artery diameter will be measured using the Sonoscope S2 ultrasound imaging system.

  3. Microdialysis perfusions [ Time Frame: 15 minutes ]
    Following recovery from the microdialysis probe insertions we will measure resting skin blood flow (SkBF).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   women
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Young women between the ages of 18 and 45 years (Controls);
  • Young women between the ages of 18 and 45 years with endometriosis.

Exclusion Criteria:

  • Subjects who smoke
  • Subjects who have diabetes,
  • Subjects with sleep apnea or BP>140/90 will be excluded.
  • Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03746535


Contacts
Layout table for location contacts
Contact: Nina Stachenfeld, MD 203-562-9901 ext 219 nina.stachenfeld@yale.edu

Sponsors and Collaborators
Yale University
Investigators
Layout table for investigator information
Principal Investigator: Nina Stachenfeld, MD Yale University
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT03746535    
Other Study ID Numbers: 2000022193
First Posted: November 19, 2018    Key Record Dates
Last Update Posted: March 23, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometriosis
Cardiovascular Diseases
Genital Diseases, Female
Ganirelix
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs